Elo Mutual Pension Insurance trimmed its stake in Vertex Pharmaceuticals by 4% in Q4, now holding $9.49 million in shares. Several other institutional investors also made notable adjustments, with ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.